Newsletter, July 2022


Update from CEO Dan J. Mogren

There is a lot going on at CLS and the future looks very exciting to us! In this newsletter, we are happy to share some company updates and insights. 

In 2021, CLS took many important steps toward fulfilling our vision to establish laser ablation as a standard treatment and as an alternative to traditional surgery for multiple patient groups. After completing more than 250 treatments with the 1st generation of our TRANBERG® Thermal Therapy System we are now approaching a full-scale commercial launch of the 2nd generation of the TRANBERG® product portfolio. 

Thanks to dedicated work by CLS R&D team and our French partner Image Guided Therapy (IGT), our treatment systems now also offer functionality for MR-based tissue temperature monitoring and control of the ablation in near real time. Through our partnerships with global suppliers of imaging and navigation technology, such as Siemens Healthineers AG and ClearPoint Neuro Inc., our systems are now also integrable with their systems used in healthcare today for imaging, navigation, and positioning.

We are proud to be one of few companies in the world developing and supplying this type of cutting-edge technology, meeting clear medical needs in many disease areas. It is very exciting times and I look forward to what the future holds for CLS.

Please do not hesitate to reach out if you have any questions to me, or anyone within the CLS team. 


Update from the clinics

Together with Skåne University Hospital, Sweden, we are now initiating our first clinical study within neurosurgery. In this study, patients with glioblastoma, an aggressive form of brain cancer, are treated with laser surgery inside the MRI scanner. This will be done using the 2nd generation TRANBERG® products, along with products for brain navigation by our partner ClearPoint Neuro. 

The advantage of using these products together is that the surgeons get access to a complete and unique high precision treatment system, enabling the entire procedure to be carried out inside the MRI suite with use of streamlined workflow. Altogether this setup has the potential of improving outcome, reducing risks and allowing for more patient groups to be treated.

The fact that Skåne University Hospital (SUS) is the first ever clinic in Sweden to conduct surgery during a MRI procedure, was covered by the local TV station SVT Sydnytt. Obviously, it is rewarding that a leading hospital such as SUS is cooperating with CLS in this groundbreaking clinical study. 

See the full story HERE (external link in Swedish).


Conferences and meetings


At the European Conference on Interventional Oncology (ECIO) that was held in Vienna in April this year, CLS had the pleasure to not only exhibit and network but also to host a hands-on workshop on focal laser ablation.

Over 60 interested interventional oncology experts were educated by our clinical application specialists about how CLS’ uniqueness in laser ablation using image guidance and temperature control can benefit their patients.



In May, CLS Americas, our subsidiary in the US, introduced our office-based system for MR/US fusion-guided high precision, focal laser ablation of soft tissue, such as prostate cancer tumors, during the AUA 2022 Conference in New Orleans. 

In the US almost 250,000 men are diagnosed with prostate cancer every year. These patients are demanding emergent therapies as alternatives to the standard treatments that have shown to carry long term harmful side effects.


Biostock Life Science Summit

Our CEO Dan J. Mogren recently presented CLS at the Biostock Life Science spring summit 2022. The presentation covers the rationale and strengths of CLS’ product portfolio as well as our three market segments with great potential: 

  • Urology – Localized prostate cancer
  • Neurosurgery – Glioblastoma & Drug resistant epilepsy
  • Oncology – Metastatic cancer

Please watch the full event below:

Meet the team

Our Clinical Application Specialists have a key role in educating and supporting users of TRANBERG® products in the start-up phase. 

Meet Mark Halberstadt, who recently joined CLS and is responsible for customer training and education in Europe. With his background as an MRI-Technician and Application Specialist, Mark contributes with invaluable experience and knowledge to the team. 

Mark, welcome to CLS! How has your first time with CLS been?

Most exciting! I have spent quite some time shadowing colleagues and learning about the product portfolio. In contrast with the MRI-scanners, the laser applicators and the clinical implementation are new to me.

The clinical team has been visiting users and validating scanners, and I am proud to be a part of that now.

Can you briefly describe your role and what expectations you have for CLS in the future?

My role is focused on clinical application of the product portfolio and customer care. Before starting each procedure, we validate the scanner, place all hardware on-site, train the user and most importantly, provide on-site support during the procedures until the customer is fully trained.

Currently, we are focusing on procedures in the prostate and brain, I foresee in the near future that due to its precision and ease of use, laser ablation will be the go-to application for many types of lesions.

Don’t forget to subscribe to our newsletter for future updates!

Sign up for our newsletter

Make sure you get all the exciting information about CLS’ progress on an ongoing basis.

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!

Please choose your country or region